Jonathan Brammer
Clinical trials sponsored by Jonathan Brammer, explained in plain language.
-
New pill trial targets rare and stubborn blood cancer
Disease control Recruiting nowThis study is testing whether a pill called ruxolitinib can help control a rare blood cancer called T-cell large granular lymphocytic leukemia (T-LGLL). It will involve about 30 adults who have low blood cell counts and need treatment. Participants will take the pill twice daily …
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New drug aims to keep cancer at bay after risky transplant
Disease control Recruiting nowThis study is testing if a drug called ruxolitinib can help patients with T-cell lymphoma stay in remission after a stem cell transplant. The drug is taken daily for a year to try to prevent the cancer from coming back and to reduce a dangerous complication where the donor cells …
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC